GVHD, previous treatment and response to ruxolitinib
| Patient . | GVHD: organ/grade . | Immunosuppression before ruxolitinib* (duration in weeks) . | Reduction of corticosteroids after ruxolitinib . | Clinical response (PR/CR) . | Time to response (wk) . | Duration of response†/current follow up (wk)‡ . |
|---|---|---|---|---|---|---|
| 1 | Intestines / IV (acute) | Steroids (4) | Yes | CR | 1 | 20/21§ |
| Cyclosporin A (3) | ||||||
| Everolimus (2) | ||||||
| ECP (3) | ||||||
| 2 | Skin / III (acute) | Steroids (18) | Yes | PR | 1.5 | 19.5/21 |
| MMF (4) | ||||||
| Cyclosporin A (4) | ||||||
| Everolimus (9) | ||||||
| ECP (11) | ||||||
| 3 | Skin / IV | Steroids (31) | Yes | PR | 1 | 15/16 |
| liver / III | UVB radiation (5) | |||||
| (acute) | MMF (4) | |||||
| MTX (2) | ||||||
| Cyclosporin A (7) | ||||||
| Everolimus (5) | ||||||
| ECP (9) | ||||||
| 4 | Skin / III | Steroids (29) | Yes | PR | 1.5 | 13.5/15 |
| intestines / IV | Everolimus (8) | |||||
| (acute) | Cyclosporin A (13) | |||||
| ECP (7) | ||||||
| 5 | Skin / III (chronic) | Steroids (44) | Yes | Response | 1 | 36/37 |
| Sirolimus (4) | ||||||
| Cyclosporin A (16) | ||||||
| MMF (61) | ||||||
| MTX (4) | ||||||
| 6 | Skin/ III (chronic) | Steroids (144) | Yes | Response | 1 | 9/10 |
| CyclosporinA (144) | ||||||
| ECP (19) |
| Patient . | GVHD: organ/grade . | Immunosuppression before ruxolitinib* (duration in weeks) . | Reduction of corticosteroids after ruxolitinib . | Clinical response (PR/CR) . | Time to response (wk) . | Duration of response†/current follow up (wk)‡ . |
|---|---|---|---|---|---|---|
| 1 | Intestines / IV (acute) | Steroids (4) | Yes | CR | 1 | 20/21§ |
| Cyclosporin A (3) | ||||||
| Everolimus (2) | ||||||
| ECP (3) | ||||||
| 2 | Skin / III (acute) | Steroids (18) | Yes | PR | 1.5 | 19.5/21 |
| MMF (4) | ||||||
| Cyclosporin A (4) | ||||||
| Everolimus (9) | ||||||
| ECP (11) | ||||||
| 3 | Skin / IV | Steroids (31) | Yes | PR | 1 | 15/16 |
| liver / III | UVB radiation (5) | |||||
| (acute) | MMF (4) | |||||
| MTX (2) | ||||||
| Cyclosporin A (7) | ||||||
| Everolimus (5) | ||||||
| ECP (9) | ||||||
| 4 | Skin / III | Steroids (29) | Yes | PR | 1.5 | 13.5/15 |
| intestines / IV | Everolimus (8) | |||||
| (acute) | Cyclosporin A (13) | |||||
| ECP (7) | ||||||
| 5 | Skin / III (chronic) | Steroids (44) | Yes | Response | 1 | 36/37 |
| Sirolimus (4) | ||||||
| Cyclosporin A (16) | ||||||
| MMF (61) | ||||||
| MTX (4) | ||||||
| 6 | Skin/ III (chronic) | Steroids (144) | Yes | Response | 1 | 9/10 |
| CyclosporinA (144) | ||||||
| ECP (19) |
ECP, extracorporeal photophoresis; MMF, mycophenolate mofetil; MTX, methotrexate; steroids, corticosteroids.
Immunosuppression before ruxolitinib represents the treatment initiated for GVHD, not prophylactic measures. aGVHD15 and cGVHD16 were defined according to National Institutes of Health criteria, which are detailed in the Methods section.
For response definitions, see detailed information in the Methods section. Until last follow-up, none of the patients experienced a relapse of GVHD.
Follow-up was calculated from the time of initiation of ruxolitinib treatment.
In patient 1, ruxolitinib was discontinued at week 16 because of complete resolution of all GVHD signs. The patient did not develop any signs of GVHD after discontinuation of ruxolitinib until last follow-up.